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The Department of Pathology and Microbiology 
is committed to providing high quality diagnostic 
services for physicians and hospitals nationwide. 
One of the functions of the Department is to 
update physicians throughout Pakistan about 
the advancement in laboratory sciences and the 
services available at the Clinical Laboratory 
for disease diagnosis, through our Laboratory 
Updates and this newsletter, LABRAD. 
The current issue of the LABRAD focuses on 
measurements related to bone disorders in an 
attempt to give readers a better understanding 
of the diagnostic modalities available at Aga 
Khan University Hospital Clinical Laboratories. 
Bone disease is a vast topic which interests a 
diverse group of medical professionals such 
as: internists, rheumatologist, orthopaedics, 
endocrinologist, gynaecologists, paediatricians 
and geriatrics, researchers in anatomy, 
physiology, nutrition, biochemistry, pathology 
and imaging. Diversity of interest is due 
to a combination of problems ranging 
from malnutrition in the developing 
world to the aging populations 
of the developed world. 
Several factors may influence the choice of a 
method for the measurement of bone disease. 
A major limiting factor in establishment of 
a service for measurement of bone diseases 
is the local availability of equipment and 
methodology, and also the availability of the 
required expertise and knowledge for the 
interpretation of results. Choice of the tests also 
depends on the type of information required 
from investigating a patient suspected of 
having a bone disease and achieving this aim as 
economically as possible in less time and money. 
This issue concentrates on common bone 
related clinical problems; focusing on practical 
usefulness of various tests available for diagnosis 
and management of bone diseases in the field. 
Biochemical bone profiles have been developed 
in the section of chemical pathology to help the 
physician in evaluating a patient suspected of 
having metabolic bone diseases. Combination of 
information on different microbiological tools 
for facilitating management of bone infection 
along with diagnostic tools available for 
identifying disorder like ankylosing spondylitis 
are also presented. On the whole this is a 
broad sweep of information collected through 
individual disciplines and we hope it will 
improve as our newsletter evolves through a 
cyclic process of learning and sharing with 
our readers.
We hope this edition would help increase your 
knowledge banks and would answer many of 
your questions. We are hopeful for making this 
issue a useful document for future reference 
in the bone disease area. Happy reading!
From the Editor’s Desk
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when we are young will help prevent problems in 
the future. 
Commonly encountered bone diseases include those
related to vitamin D deficiency (rickets in children and 
osteomalacia in adults), osteoporosis, osteogenesis, 
imperfecta and Paget’s disease of bone. Bone disease 
can lead to fragile and brittle bones, which break easily.
AKUH clinical laboratory is now providing Bone 
Health Panel, (please refer to the table below) which 
helps in assessment of bone health. This profile is 
intended to screen, investigate and monitor patients 
with disorder of calcium and bone metabolism. It 
provides answer to the potential clinical questions 
that a physician seeks when investigating for 
metabolic bone diseases for example; does my patient 
have hypocalcaemia or hypercalcaemia? If there is 
hypercalcaemia, is it due to hyperparathyroidism or 
a parathyroid hormone independent cause? If it is 
hypocalcaemia, is it due to parathyroid failure, vitamin 
D deficiency or renal failure? Does my patient have 
hypomagnessemia? If the patient has aches and pains 
or unexpected fracture then is it due to metabolic 
bone disease? 
Osteoporosis Panel
Osteoporosis is a systemic skeletal disorder 
characterised by low bone mass and micro architecture 
The utility of bone profiles in screening and diagnosis 
of bone diseases have a profound effect upon bone 
health. Choosing any screening profile helps to rule  out 
metabolic bone diseases such as vitamin D deficiency, 
osteoporosis. Panels are made to make clinical 
interpretation easy for physicians and economical 
for patients. 
Following profiles are available at Clinical Laboratory 
AKU for diagnosis and monitoring of bone disorders. 
Only 5 ml of blood is sufficient for any one of the 
panel as shown in the table.
Bone Health Panel
Bone health is important throughout the lifetime of 
an individual. Bones protect our internal organs from 
damage, they are the factory of our blood cells and 
are the storehouse for minerals and nutrients (such as 
calcium and phosphorus) needed in the body. With all 
of these critical functions for our health, understanding 
how to maintain and build healthy bones is an important 
part of investigating for a healthy future.
It is especially important to build strong and healthy 
bones during childhood and teen years to avoid 
osteoporosis and other bone problems later in life. 
After the mid-30s, bone loss slowly begins to occur.
Women lose bone quickly after menopause. 
Importantly, healthy habits can help to limit the 
bone loss that occurs. Taking care of our bones 
Biochemical Bone Profiles Available at Clinical 
Laboratory of Aga Khan University Hospital
Dr Farhan Javed Dar
Chemical Pathology
BIOCHEMICAL BONE PROFILE
Bone Health Panel Osteoporosis Panel
Calcium Calcium
Phosphorus Phosphorus
Albumin Albumin
Magnesium Alkaline phosphatase (ALP) 
Alkaline phosphatase (ALP) 25-hydroxy vitamin D (25-OHD) 
Creatinine  Intact parathyroid hormone (iPTH)
Intact parathyroid hormone (iPTH) N-telopeptide of type I collagen (NTx)
25-hydroxy vitamin D (25-OHD) 
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deterioration of bone tissue with a consequent increase 
in bone fragility and susceptibility to fracture.
According to WHO by 2025, almost 3 million of 
the global population will suffer from osteoporosis 
which will be expected to rise to 6.3 million by 2050. 
About 75 percent of this 6.3 million hip fractures 
will occur in the developing countries, mainly due 
to projected large increase of aged population. 
Osteoporosis is a costly disease due to its chronic 
nature, severity of its complications and means 
required to treat it. Osteoporosis is diagnosed  late as 
patient remains asymptomatic until fracture occurs. 
AKUH Clinical Laboratory is providing Osteoporosis 
Panel, mentioned in the above table, which helps in 
assessment of osteoporosis. 
It is to be noted that diagnosis should be made in 
correlation with clinical picture and Dual-energy 
X-ray absorptionetry (DXA) results. 
Plasma calcium exists in three forms ionized (iCa) 
(45 to 50 per cent), protein bound (40 per cent) and 
calcium complexed with anions (10-15 per cent). 
Although all the forms are in equilibrium with 
each other, only the plasma iCa has been reported 
to be active at cellular level. This parameter has 
also been called ‘free’ or ‘ionic’ calcium. It is 
considered the best indicator of calcium status 
because it is biologically active and tightly 
regulated by parathyroid hormone (PTH) and 
1, 25 dihydroxy vitamin D. Total calcium level 
does not give an indication of what is available 
at the cellular level. Only disturbances in iCa 
are physiologically relevant.   
Dr Lena Jafri
Chemical Pathology
Ionized Calcium Determination in Clinical 
Labortory
Analysis of iCa is technically demanding. The sound 
analytical performance of today’s iCa analyzers using 
ion selective electrode (ISE) technology have made 
measurements accurate and precise. iCa recently 
introduced in Aga Khan University Clinical Laboratory 
after thorough research and understanding of Clinical 
Laboratory Standard Institute Guidelines (CLSI) for 
sample handling, storage and transportation. Table 
1 shows the precautions to be taken prior to blood 
sampling for iCa determination and collection.
The clinical usefulness of measuring iCa rather 
than total calcium is more in disorders with plasma 
protein abnormalities like liver failure, protein losing 
Table 1. Recommendations for specimen collection of iCa as per CLSI guidelines
Collection Techniques
 If a series of tubes must be collected, fill gel tube  
 for iCa first
 Do not leave the tourniquet on for more than 3   
 minutes
 Do not allow the patient to exercise the forearm    
 or make a fist
 Fill gel tubes completely
 Handle specimen anaerobically (do not open the   
    tube until analysis)
Have the patient rest for 5-10 min before 
collecting blood 
Ensure that the patient has not eaten for at 
least 4 hours 
Collect specimens under consistent conditions 
ideally the patient should be seated
Precollection Variables and 
Recommendations
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Parathyroid Hormone Disorders and Issues 
of Testing
Dr Syed Talha Naeem
Chemical Pathology
Parathyroid hormone (PTH) is secreted by the 
parathyroid glands and regulates serum calcium (Ca) 
through its effects on the bone, kidney and intestine. 
PTH secretion is stimulated by decrease in serum Ca 
and magnesium and an increase in serum phosphate, 
which in turn raises serum ionized Ca levels through 
direct action on bone and the kidneys. Long-term 
regulation of total body Ca by PTH occurs through its 
stimulation of vitamin D metabolism. 
PTH can be measured in the blood in several 
different forms: intact PTH; N-terminal PTH; mid-
molecule PTH, and C-terminal PTH. An intact 
PTH (iPTH) provides a better index of parathyroid 
function and is the test available in AKUH clinical 
laboratory for clinical use. 
PTH is secreted in episodic or pulsatile fashion 
with an overall circadian rhythm characterised by 
a nocturnal rise. Measurement of iPTH on more 
than one occasion should minimise the effect of 
episodic secretion and circadian rhythm. Because 
of the nocturnal rise in iPTH levels, samples should 
be collected in the morning, preferably after an 
overnight fast.
Determination of iPTH is useful in the differential 
diagnosis of disorders of bone and mineral 
metabolism, including hypocalcaemia and 
hypercalcaemia, renal failure and secondary 
hyperparathyroidism; when PTH increases long 
before Ca becomes abnormally low. 
PTH is elevated in the majority of patients with 
primary hyperparathyroidism. It is below normal 
or in the lower half of the reference interval in 
most patients with nonparathyroid hypercalcemia 
including hypercalcemia-associated malignancy. 
In cases with hypercalcemia, PTH estimation 
should be performed before initiating any therapy 
to reduce serum Ca; as PTH secretion may be 
stimulated by declining but still elevated levels 
of serum Ca. This can complicate the differential 
diagnosis of hypercalcaemia. In the majority 
of patients with hypercalcaemia associated 
with malignancy, iPTH is suppressed to levels 
below normal or at the lower end of the normal 
reference interval. Elevated levels of iPTH in 
patients with hypercalcemia and malignancy 
suggest coexisting hyperparathyroidism and 
malignancy, because ectopic PTH production 
appears to be extremely rare. 
In secondary hyperparathyroidism, iPTH is increased 
before total or free calcium becomes abnormally 
low, a consequence of homeostatic mechanisms 
nephropathy, burns, cardiac failure or malnutrition. 
iCa determination is more useful in those undergoing 
major surgery who have received citrated blood/
platelets, heparin, or intravenous calcium.
It should be the test of choice when neonatal 
hypocalcemia is suspected, especially if bicarbonate 
is given to neonates with hypocalcemia.
Rapid measurement of iCa in intensive care units is 
helpful in cases with sepsis and acid base disturbances. 
It has been documented that the use of total calcium 
is unreliable in cases where there is a change in the 
protein-calcium binding characteristics as in patients 
with hypergammaglobulinemia or a decrease/increase 
in pH. An increase in blood pH is associated with a 
decrease in iCa a decreased blood pH is associated 
with an increased iCa.
Ionized calcium is also useful in cardiopulmonary 
bypass and during hemodialysis where maintenance 
of good cardiac function is essential. During 
dialysis monitoring a slight positive calcium 
balance is important for maintaining good cardiac 
contractility. Ionized calcium is the best means to 
monitor this.
Literature shows that iCa rather than total 
calcium is more useful  in malignancies,  hypo/
hyperparathyroidism and pancreatitis.
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for maintenance of serum Ca. Consequently, 
PTH is more sensitive than Ca for identifying 
secondary hyperparathyroidism. Subnormal or 
normal PTH is observed in the majority of patients 
with hypoparathyroidism; such concentrations are 
inappropriately low for patients with hypocalcemia.
In patients with end-stage renal disease, measurement 
of iPTH is helpful in assessing parathyroid function, 
in estimating bone turnover, and in improving 
management. Patients with high turnover bone disease 
because of secondary hyperparathyroidism (advanced 
osteitis fibrosa) have the highest concentrations of 
PTH, whereas patients with low-turnover, adynamic 
bone disease, including osteomalacia, have the lowest 
concentrations. Intermediate levels are found in 
patients with low-turnover adynamic (aplastic) disease 
and early osteitis fibrosa. Considerable overlap in 
iPTH levels is apparent between the various forms of 
renal osteodystrophy. 
iPTH is also useful intraoperatively, for assessing the 
completeness of parathyroidectomy and facilitating 
minimally invasive parathyroid surgery, thereby 
improving cost-effectiveness and cosmetic outcomes.
PTH levels may be altered in some patients 
with hyperthyroidism and hypothyroidism 
and may increase after treatment with lithium 
carbonate. PTH concentrations are inversely 
correlated with T3 levels in hyperthyroid 
patients, increase in patients who become 
hypothyroid after radioactive iodine treatment, 
and decrease with replacement therapy; changes 
apparently mediated by serum Ca. Chronic 
lithium carbonate therapy has been reported to 
increase parathyroid gland size and circulating 
intact PTH. Drugs that may increase PTH levels 
include phosphates, anticonvulsants, steroids, 
isoniazid, lithium, and rifampicin.
Because of the physiological relationship 
between circulating Ca and PTH, it is always 
important to interpret PTH results in the light 
of total or ionized Ca levels. Indices of renal 
function, measurements of albumin, as an 
adjunct to measurement of total calcium levels 
and determinations of phosphorus, chloride, 
and magnesium levels may also aid in the 
interpretation of PTH and Ca results. It should 
also be remembered that hypercalcemia and 
hypocalcemia may be secondary to disordered 
vitamin D metabolism. For diagnostic purposes 
PTH results should always be used in combination 
with the clinical examination, patient medical 
history, and other findings.   
Tubular maximum reabsorption rate of phosphate 
to glomerular filtration rate (TmP/GFR)
Phosphate filters entirely through the glomeruli 
but is then largely reabsorbed in the proximal 
part of the proximal renal tubule. Several factors 
influence the tubular reabsorption of phosphate 
(Table 1) by acting on the sodium/phosphate 
co transporters.
Tubular reabsorption of phosphate depends on 
plasma phosphate and glomerular filtration rate and 
is not a satisfactory indicator of tubular phosphate 
handling. This has led to increasing use of ‘tubular 
maximum for phosphate corrected for GFR (TmP/
GFR)’, a factor independent of plasma phosphate 
and renal functions for assessment of renal phosphate 
handling. TmP/GFR (Normal 2.8-4.4 mg/dL) is an 
index of renal threshold for phosphate which can 
be determined directly by the formula TmP/GFR 
= Plasma phosphate - (urine phosphate x serum 
creatinine)/urine creatinine.
Assessing renal reabsorption of phosphorus is 
needed in a variety of pathological conditions 
associated with hypophosphatemia including 
hypophosphatemic rickets, tumour-induced 
osteomalacia and tumoral calcinosis. It is also used 
in adjusting phosphate replacement therapy in 
severe deficiency states; like conditions that cause 
phosphate redistribution (e.g. glucose infusion, 
respiratory alkalosis), so if hypophosphataemia 
persists, a low (fasting) TmP/GFR indicates the 
Dr Noreen Sherazi
Chemical Pathology
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need for phosphate replacement. In the treatment 
of severe phosphate deficiency, TmP/GFR can be 
used as an indicator of intracellular repletion. 
The measurement of TmP/GFR along with other 
parameters is required for diagnosis of X-linked 
hypophosphataemic rickets and hereditary 
hypophosphataemic rickets with hypercalciuria. 
Measurement of TmP/GFR is central to the diagnosis 
of oncogenic osteomalacia in addition to other 
parameters
We, at AKUH clinical laboratory, are starting this 
test which will required at least 6-8 hours fasting 
serum sample for phosphate and creatinine and 
simultaneously taken spot urine sample for phosphate 
and creatinine. TmP/GFR will then be calculated 
from above mentioned parameters.
LABRAD Quiz
Dr Hafsa Majid
Chemical Pathology
Table 1. Factors affecting tubular reabsorption of phosphate
Factors that decrease renal phosphate absorption
Phosphate-free diet
Respiratory acidosis, metabolic alkalosis
PTH, PTHrP, EGF, glucocorticoids, catecholamines, 
calcitonin, 1,25(OH)2 D3
Diuretics
Phosphatonins
Factors that increase renal phosphate absorption
High dietary phosphate intake
Respiratory alkalosis, metabolic acidosis
GH, IGF1, thyroid hormones (T3), insulin
Question #1
A three-week-old girl was brought to the emergency 
room because of intermittent twitching of her left 
limbs for 4 days. The girl had been born normally 
at 39 weeks of gestation and was being breast-fed. 
Examination was unremarkable. Her biochemical 
investigations were:
Na+ : 125mmol/l (135-145 mmol/l)  
Cl- : 100mmol/l (101-111 mmol/l)  
K+ : 2.8mmol/l (3.6-5.0 mmol/l)
HCO3 : 30mmol/l (23-28 mmol/l)
Ca+ : 4.5mg/dl (8.4-10.2mg/dl)  
Albumin : 2g/dl (3.2-5.5g/dl)
PO4 : 10mg/dl (2.5-4.6 mg/dl)
PTH : <4pg/l (16-87pg/ml) 
1.1: What is the diagnosis?
1.2: Which other bone mineral is required for   
 optimal parathyroid function?
1.3: How would this be treated?
Question #2 
A 60-year-old female came to ER due to fracture 
neck of femur after a minor fall. Her past 
complaints were of generalised body aches and 
bone pains with difficulty in rising from sitting 
position since two year.  She was a known case 
of hypertension for the past 20 years and taking 
antihypertensive since then. She was diagnosed 
to be osteoporotic and was considered for 
bisphosphonate therapy. 
2.1: What is the most likely cause of body aches  
 in the patient?
2.2: What biochemical test can be performed to  
 confirm diagnosis?
2.3: How will you monitor the response to   
 bisphosphonate therapy?
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Renal Osteodystrophy:  A Disturbed Metabolic 
Aspect of Renal Failure
Renal osteodystrophy is a common complication 
of chronic kidney disease (CKD). It is part of a 
broad spectrum of disorders of mineral and bone 
metabolism that develop in this clinical setting 
and result in both skeletal and extra skeletal 
consequences. The term CKD-Mineral and 
Bone Disorder (CKD-MBD) has been recommended 
to be used to describe a broader clinical 
syndrome that develops as a systemic disorder of 
mineral and bone metabolism in CKD. The 
manifestations include abnormalities of calcium, 
phosphorous, parathyroid hormone (PTH) or 
vitamin D metabolism; abnormalities in bone 
turnover, mineralisation, volume, linear growth 
or strength; and vascular or other soft tissue 
calcification. 
The term renal osteodystrophy should be used 
exclusively to define alterations in the bone 
morphology associated with CKD. This is a 
single measure of the skeletal component of 
the systemic disorder of CKD-MBD that is 
quantifiable by histomorphometry of bone biopsy. 
The abnormalities of the bone in the setting of 
CKD may manifest as high turnover bone disease 
(ostietis fibrosa or secondary hyperparathyroidism), 
dynamic bone disease, osteomalacia and mixed 
renal osteodystrophy.
Biochemical markers for diagnosing renal 
osteodystrophy are intact PTH (iPTH), vitamin D 
(25OHD), blood calcium and phosphorus levels 
and bone turn over markers such as alkaline 
phosphatase and N-telopeptide of type I Collagen 
(NTx).  
              
The pathogenesis of osteodystrophy is complex. 
The cycle starts with the renal failure and retention 
of phosphate, inhibiting calcitriol (1,25 dihydroxy 
vitamin D) synthesis and decrease in calcium 
through a reduction in intestinal calcium absorption. 
Hypocalcaemia stimulates PTH secretion causing 
high turnover renal osteodystrophy.  
The biochemical picture of high turnover renal 
osteodystrophy usually is an increase in blood 
PTH, bone alkaline phosphatase and phosphate 
concentration and low calcium and 25OHD 
levels.
Low turnover bone disease is commonly observed 
in dialysis patients, but has been described in 
some cases even before dialysis. Adynamic bone 
disease is associated with the over suppression 
of parathyroid gland activity due to high calcium 
intake (from diet, dialysate or calcium-containing 
phosphorus binders) and/or administration of 
vitamin D analogs in excess.
Patients with adynamic bone disease have lower 
blood concentrations of iPTH that may fall 
below the recommended target range of 150-
300 pg/ml of iPTH, resulting in a bone turnover 
rate that is below normal. In these circumstances, 
the bone may not take up calcium for incorporation 
into new bone and any excess calcium may 
predispose to calcification in soft tissues. 
Currently in the United States, approximately 
25 per cent of patients undergoing dialysis have 
a iPTH concentration above the target range 
(high-turnover disease), approximately 25 
per cent have a PTH concentration within the 
target range and 50 per cent have a PTH 
concentration below the target range (adynamic 
bone disease).
The ultimate goal of drug therapy in the 
management of CKD is to prevent complications 
of CKD, specifically bone disease and extra 
skeletal calcification. Need for the evaluation, 
treatment and monitoring of bone metabolism is 
to prevent secondary hyperparathyroidism. At 
stage 3 CKD, serum calcium, phosphorus and 
iPTH concentrations should be evaluated. After 
initial assessment, routine monitoring should be 
performed (see table 1). Appropriate management 
requires a balanced diet, phosphorus binders and 
active vitamin D analogs. The recommended 
ranges for corrected calcium, phosphorus and 
iPTH for different stages of CKD for kidney 
diseases outcomes quality initiative are shown in 
Table 2.
Dr Sahar Iqbal
Chemical Pathology
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Table 1. Monitoring of frequency of calcium, phosphorus and intact PTH in different stages of CKD kidney diseases
National kidney foundation. Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12
 Stage of CKD Measurement of iPTH Measurement of calcium and 
  phosphorus
 3 (30-59 ml/min/1.73 m2 Every 12 months Every 12 months
 4 (15-29 ml/min/1.73 m2 Every 3 months Every 3 months
 5 (<15ml/min/1.73 m2 Every 3 months  Every month
Table 2. Recommended ranges for phosphorus, corrected calcium and PTH for different stages of CKD.
National kidney foundation.  Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12
Stage of CKD Phosphorus Corrected calcium  Serum PTH
 (mg/dl) (mg/dl) (pg/ml)
3 (30-59 ml/min/1.73 m2 2.7-4.6 Normal range 35-70
4 (15-29 ml/min/1.73 m2 2.7-4.6 Normal range 70-110
5 (<15ml/min/1.73 m2 3.5-5.5 8.9-9.5 150-300
Beta thalassemia major (TM) is an inherited autosomal 
recessive disorder in which synthesis of beta globin 
chains is compromised due to mutation of beta globin 
gene culminating in ineffective erythropoiesis.
The anaemia manifests at 6 to 9 months after 
birth as haemoglobin switches from HbF to HbA 
with features like failure to thrive, poor feeding, 
recurrent infections, pallor and enlarged spleen. In 
untransfused patients haemoglobin level ranges from 
3 to 6 gm/dl. However, regular blood transfusion and 
compliance with prompt iron chelation therapy has 
markedly improved life expectancy of thalassemics, 
but morbidity due to its chronic complications like 
osteopenia and osteoporosis remains there.
Osteopenia refers to bone mineral density (BMD) 
that is lower than normal peak BMD but not low 
enough to be classified as osteoporosis while 
osteoporosis is characterised by low bone mass 
and disruption of bone architecture, resulting in 
decreased bone strength with an increased risk 
of fracture.
The frequency of osteopenia or osteoporosis in 
well-treated patients of TM is approximately 
40-50 per cent which clearly depicts that despite 
the normalisation of haemoglobin levels, adequate 
hormone replacement and effective iron chelation; 
thalassemics continue to show an unbalanced bone 
turnover and an increased resorption resulting 
in seriously diminished BMD. Bone disease in 
thalassemia is manifested by diffuse bone pain, 
spinal deformities like scoliosis, nerve compression 
and various degrees of osteopenia, osteoporosis 
and spontaneous fractures. 
Osteopenia and Osteoporosis in Beta 
Thalassemia Major
Dr Huma Mansoori and Dr Shabina Sikandar
Haematology
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Role of β2 Microglobulin in Multiple Myeloma
Dr Mehreen Imran
Haematology
Factors contributing to osteoporosis and osteopenia 
in thalassemics include iron overload resulting in 
endocrinopathies; which directly or indirectly leads 
to decreased bone mass. There is marrow expansion 
due to increased erythropoiesis causing mechanical 
interruption of bone formation leading to cortical 
thinning of bones. In addition, osteoblasts are also 
affected by direct iron toxicity as well as due to liver 
disease. Chelation therapy with desferrioxamine 
inhibits DNA synthesis, osteoblast and fibroblast 
proliferation, osteoblast precursor’s differentiation 
and collagen formation, whereas in high doses it 
enhances osteoblast apoptosis.
The serum biochemistry is usually unhelpful in 
diagnosis of osteoporosis because the levels of 
calcium, phosphate and PTH are generally normal. 
However, markers of bone turnover such as serum 
alkaline phosphatase, serum osteocalcin, and N 
telopeptide of Type I Collagen (NTx) may be raised 
in osteoporosis in TM. Dual energy x-ray absorption 
(DXA scan) is also commonly used to assess bone 
mineral density but it should be kept in mind that it 
may fail to provide accurate and precise information 
on osteoporosis in thalassemics as they have spinal 
degenerative skeletal changes, which can be detected 
only by MRI and is likely to interfere with BMD 
values, resulting in false diagnosis of bone disease. 
Vitamin D deficiency can also co-exist.
Following therapeutic strategies should be undertaken 
to prevent and treat osteopenia/osteoporosis in TM.
l lifestyle measures should be encouraged such as 
 physical activity and smoking quitting.
l calcium and vitamin D intake during skeletal 
 development increases bone mass in adult life with 
 the final goal to prevent bone loss and fractures.
l induction of puberty at a proper age and 
 treatment of hypogonadism with hormone 
 replacement therapy shows quite promising results 
 to prevent osteoporosis and other bone deformities. 
l calcitonin, a potent inhibitor of osteoclasts, in 
 combination with calcium and vitamin D has 
 shown to decrease bone pain and radiological 
 signs of osteoporosis.
l alendronate, pamidronate, and zoledronic 
 acid have shown efficacy in osteoporotic patients 
 with TM either with normal or impaired gonadal 
 function but further research in the therapeutic 
 trials with bisphosphonates is needed to allow 
 definite conclusions especially in our setting 
 where vitamin D deficiency is widely prevalent. 
 However, they may be used as a second line 
 treatment if the above strategies have failed.
Multiple myeloma is a B cell malignancy characterised 
by monoclonal accumulation of abnormal plasma 
cells in the bone marrow (Fig. 1). The clinical signs 
and symptoms of myeloma are heterogeneous and 
include bone complications, symptoms of impaired 
formation of blood cells and hyperviscosity, renal 
dysfunction, infections, peripheral neuropathy and 
extra medullary disease.
Multiple myeloma constitutes about 15 per cent of the 
haematological malignancy. The disease develops in 
one to four per 100,000 people per year. It is more 
common in men, and is twice as common in blacks as it 
is in whites. With conventional treatment, the prognosis 
is three to four years, which may be extended to five 
to seven years or longer with advanced treatments.
Diagnostic work up for myeloma is shown in Table 1. 
One of the laboratory parameter is β2 microglobulinFig. 1. Bone marrow aspirate demonstrating plasma cells of multiple myeloma
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multiple myeloma patients. Increased production or 
destruction of plasma cells causes β2 microglobulin 
level in the blood to increase. Pre-treatment values 
of β2 microglobulin are thus useful in confirming 
tumor mass grade, and in assessing response 
to chemotherapy; marked reductions following 
chemotherapy correlated well with the onset of 
remission. The serum β2 microglobulin level is 
one of the prognostic factors incorporated into the 
International staging system. Patients with high 
values have inferior survival.
The following levels of β2 microglobulin correlate 
with stages of multiple myeloma:
Stage I multiple myeloma
l β2 microglobulin level is lower than 3.5 mg/mL
l albumin level is 3.5 g/dL or higher
Stage II multiple myeloma
l β2 microglobulin level is lower than 3.5 mg/mL  
 and the albumin level is lower than
 3.5 g/dl
l β2 microglobulin level is between 3.5 and 5.5  
 mg/mL
Stage III multiple myeloma
l β2 microglobulin is 5.5 mg/mL or higher. 
 
The prognostic value of serum β2 microglobulin 
level in myeloma is probably due to correlation 
of levels with tumour burden. High levels are also 
associated with renal failure, which carries an 
unfavourable prognosis in multiple myeloma. The 
reference ranges are shown in table 2.
β2 microglobulin test is performed by a chemilumniscent 
assay in Clinical Laboratory AKUH. It is done on 
clotted blood sample of the patient; however, it can 
also be performed on patient’s urine. Urine may be 
a single collection or collected throughout a 24 hour 
time period. The urine should be refrigerated until it is 
brought to the laboratory and must not become acidic. 
   ng/mL
Group Median 2.5%ile 95%ile 97.5%ile N
Table 2. Reference ranges for β2 microglobulin as reported in AKU-Laboratory
Males 1,556 604 2,157 2,284  424
Females 1,473 607 2,295 2,454 370
Laboratory Tests
Full blood count, peripheral film and ESR
Evaluation of kidney function, serum calcium, CRP, 
β2 microglobulin, LDH, uric acid levels and liver 
function tests
Protein electrophoresis and paraprotein quantification
Quantitative analysis of normal immunoglobulins,
24-hours urine collection for light chain (Bence Jones 
protein) excretion, coagulation screen
Bone marrow aspiration and trephine biopsy for 
morphology, immunophenotyping (CD138, CD79a, 
kappa, lambda, CD20) and cytogenetic
Radiological Tests
Complete skeletal survey
Computerised tomography (CT)
Magnetic resonance imaging (MRI)
(also known as β2M) is a component of MHC 
class I molecules, which are present on all white 
blood cells (including plasma cells). In humans, 
the β2 microglobulin protein is encoded by the β2 
microglobulin gene 
(Fig. 2). Normal 
urinary excretion of β2 
microglobulin is less 
than 370 micrograms 
per 24 hours. Elevated 
serum concentration in 
the presence of normal 
glomerular filtration 
rate suggests increased 
β2 microglobulin 
production or release, 
which is seen in 
lymphoproliferative 
diseases such as 
multiple myeloma. 
The increase is seen 
in cancers involving 
white blood cells, 
but it is more meaningful in newly diagnosed 
Table 1. Laboratory and radiological work ups for multiple mayeloma 
available at AKUH
Fig. 2. Structure of MHC class I β2     
microglobulin
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Prosthetic joint infections (PI) are associated with 
substantial morbidity and costs; therefore early and 
accurate diagnosis is crucial. The clinical presentation 
may be non-specific and vary between different patient 
populations. Effective use of the currently available 
diagnostic modalities for PI results in improves 
outcomes. PI occurring within three months of joint 
replacement are categorized as early and 3-12 months 
after surgery as delayed and >12 months as late.
A widely accepted case definition for PI includes: 
l purulence around a prosthesis at arthrotomy or  
 arthroscopy
l presence of one or more sinus tract    
 communicating with the joint
l histological features of infection
l isolation of similar organism from at least two  
 deep culture samples. Isolation of virulent   
 organisms, such as Staphylococcus aureus,   
 Escherichia coli, or Candida spp., in one deep 
 tissue sample may be considered as significant 
 to confirm the diagnosis. 
Gram positive organisms, especially Staphylococci 
(commensal skin organisms), are most commonly 
involved and in early infection, pathogens are usually 
more virulent (for example, Staphylococcus aureus),
Update on Microbiological Diagnosis of Bone 
and Joint Disorders
Dr Kauser Jabeen
Microbiology
whereas more indolent organisms predominate later 
on (for example, coagulase negative staphylococci, 
Propionibacterium acnes) (Table 1). 
Laboratory investigations
Detection of inflammatory markers:
Baseline blood tests for inflammatory markers including 
C reactive protein (CRP), erythrocyte sedimentation 
rate (ESR), leukocyte count should be performed 
for any suspected case. These parameters may be 
elevated up to two weeks after surgery and cannot be 
relied upon in early infection. Serial measurements 
of these markers are recommended and persistently 
or progressively high inflammatory markers most 
likely reflect infection. It is important to note however, 
that a normal result does not exclude joint infection 
especially if the pathogen is of low virulence. 
Cultures:
Blood for culture should be taken in every case 
before starting antibiotics as even a single dose is 
known to decrease the diagnostic yield. In most 
cases however, it is difficult to take deep cultures 
before starting antibiotics in patients with systemic 
sepsis or rapidly evolving 
local infection. 
Superficial swabs should 
not be collected as they most 
likely reflect colonising 
flora and results must 
therefore be interpreted 
with caution. Deep samples 
of synovial fluid and tissue 
taken during arthrotomy/
arthroscopy, or by joint 
aspiration are needed 
for definitive diagnosis. 
Organisms should be identified accurately as treatment 
Prosthetic joint infections; How to effectively use the available 
diagnostic modalities?
Gram positive organisms Gram negative organisms Fastidious organisms
Coagulase negative staphylococci Enteric Gram negative bacilli Anaerobes
Methicillin sensitive Pseudomonas spp Mycobacteria
Staphylococcus aureus 
  
Methicillin resistant S aureus   Fungi
Streptococcus spp   
Enterococcus spp   
Diphtheroids (Corynebacterium 
spp, Propionibacterium spp) 
Table 1. Organisms commonly involved in prosthetic joint infections
14
September 2011, Vol. 37, Issue 2
Other diagnostic modalities:
Apart from culture histopathology is an essential 
adjunct to microbiology in the diagnosis of infection. 
An elevated white cell count and neutrophil differential 
of the synovial fluid are also suggestive of infection. 
Serial plain radiographs may help in detecting 
loosening or bone loss in chronic PI. Ultrasound 
should be performed to confirm effusion and to 
facilitate aseptic aspiration. Computed tomography 
and magnetic resonance imaging may be useful in 
the evaluation of complex cases, but metal inserts 
interfere with these tests, and abnormalities may be 
non-specific.
options differ for different organisms (Fig.1 and Fig. 2). 
Identification of similar organisms from at least three 
culture samples is highly predictive of infection and 
to increase sensitivity and specificity multiple (five 
to six) samples should be sent for culture. Organisms 
associated with prosthetic-joint infection usually form 
biofilms thus culture of prosthesis by vortexing and 
sonication than conventional peri-prosthetic tissue 
culture is more sensitive and specific especially in 
patients with prior antibiotic treatment. Cultures 
should also be hold for longer duration if fungi or 
mycobacteria are suspected as causative organisms.
Fig. 1. Coagulase test that is required to differentiate between Staphylococcus 
aureus and other Staphylococcus species; two most common organisms respon-
sible for prosthetic joint infections. Upper tube is coagulase positive confirming 
the identity of this organisms as Staphylococcus aureus
Fig. 2. Photomicrograph on the left showing Gram stain of Propionibac-
terium species; this organisms requires anaerobic conditions
Bone and joint infections: Laboratory Diagnosis
Bone and joint infections occur as a result of 
haematogenous seeding, contiguous spread of 
infection to bone from adjacent soft tissues, or direct 
inoculation of infection as a result of trauma or surgery. 
Haematogenous spread is more common in children 
while contiguous spread is commoner in adults. 
Contiguous infection may be either polymicrobial 
or monomicrobial while haematogenous infection 
is usually monomicrobial. Staphylococcus aureus, 
coagulase-negative staphylococci, and aerobic gram-
negative bacilli are the most common organisms; less 
common pathogens include streptococci, enterococci, 
fastidious gram negative organisms and anaerobes. 
Mycobacteria, Brucella spp. and fungi have also been 
reported in appropriate endemic and clinical settings.
Diagnosis; General Considerations
Cultures: Several factors should be considered while 
investigating for the diagnosis of these infections. 
The most important factor is specimen collection as 
it is extremely important to prevent contamination 
by normal flora. The samples should be collected as 
tissue or fluid rather than swabs because:
l they are more likely than tissue or fluid to be  
 contaminated
l the amount sent for culture is often insufficient
l they may inhibit the growth of certain   
 pathogens
l fastidious organisms survive less well in   
 swabs than in aspirated fluid or pus
l bacteria may adhere to swabs and give a   
 false-negative microscopy result
Ideally, culture specimens should be taken before 
antibiotics are commenced. In practice, however, 
empirical antibiotics may be commenced before 
culture specimens are taken.
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Bone and Joint Infections: Laboratory Diagnosis
If Mycobacteria or fungi are suspected as etiologic 
agents; specimens should be sent for mycobacterial 
and fungal culture in addition to culture for 
routine organisms. 
Histopathology: Histopathology and cytology not 
only provide rapid results than culture but also 
guide in assessing the significance of cultures. 
However the tissue Gram stain is an insensitive 
test for detecting bacteria as fixing and processing 
including chemical decalcification, adversely 
affects the Gram stain characteristics. 
Nucleic acid amplification tests: There is little 
published information regarding the role of nucleic 
acid amplification based methods for skin, bone, joint, 
and soft-tissue infections. Therefore, routine use of 
nucleic acid amplification is not recommended for the 
diagnosis of these infections. Although these techniques 
may prove useful in selected cases where fastidious 
organisms are suspected as cause of infection. 
Bone Infections
Close communication between clinician, radiologist 
and pathologist/microbiologist is required for optimum 
diagnosis. Excisional bone biopsy is required in cases 
in which clinical and radiographic features are not 
diagnostic. In all cases however, culture is essential 
for identification and antimicrobial susceptibility 
testing. For that an adequate amount of tissue should 
be sent to the microbiology laboratory. For chronic 
osteomyelitis, culture of an infected bone specimen 
is necessary to establish the diagnosis. Blood culture 
should also be sent to aid the diagnosis if the patient is 
septic. A positive culture precludes the need for more 
invasive procedures if the organism isolated from 
blood is a likely pathogen to cause osteomyelitis.
Cultures of superficial wounds and sinus tracts are 
of no value because the results do not correlate 
reliably with the pathogen in the underlying bone 
except if Staphylococcus aureus or Salmonella spp 
are isolated (Fig. 1). 
Serial measurements of serum C-reactive protein 
levels and erythrocyte sedimentation rates are also 
commonly used to monitor response to therapy. The 
CRP is a more sensitive parameter than the ESR.
Joint Infections
Synovial fluid analysis is useful in establishing 
diagnosis and presence of pus suggest  the possibility 
of infection (Fig. 2). Joint fluid should be cultured 
for both aerobic and anaerobic bacteria. Blood 
culture bottles should not be used to culture joint 
fluid as they have not been evaluated for yield for 
culturing joint fluid (Fig. 3). Fluid aspirated from 
joints should be collected aseptically, transferred 
to a sterile container (or left in the syringe), and 
sent immediately to the laboratory. Cultures for 
Neisseria gonorrhoeae should be transported 
immediately to the laboratory. Specimens to be 
submitted for mycobacterial culture do not require 
special handling. 
Fig. 1. Swabs from superficial wounds and sinus tract should not be sent 
as the organisms isolated do not correlate with the pathogen in bone
Fig. 3. Blood culture bottles should not be used to culture joint fluid; 
fluid aspirated should be transferred to a sterile container
Fig. 2. Pus sample aspirated from infected knee joint highly suggestive of 
infection. Photomicrograph on the right is showing Gram stain of same 
sample revealing numerous pus cells and Gram positive cocci in clusters
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Mycetoma is a chronic inflammation of skin 
and subcutaneous tissue caused by either 
fungi (eumycetoma) or filamentous bacteria 
(actinomycetoma). This infection most commonly 
presents as a progressive, subcutaneous swelling with 
development of multiple nodules. These nodules later 
develop into sinuses with discharging grains (Fig. 1). 
As the disease progresses involvement of bones and 
in advanced cases osteoporosis and bone destruction 
can occur. The organisms responsible for mycetoma 
are present in the soil and enter the subcutaneous 
tissue by traumatic inoculation. This infection is 
mainly seen in tropical regions and Pakistan is one 
of the endemic countries. Mycetoma commonly 
affects adults aged 20 to 40 years, predominantly 
males. The foot is the most commonly affected site 
(80 per cent of the cases). 
Diagnosis
Diagnosis is usually determined clinically; however 
radiology is required to assess the extent of 
spread and involvement of bone and joints. Visual 
examination of colour of discharging grains is crucial 
for identification of possible etiologic agent (Fig. 2). 
In addition to that microscopic examination after 
crushing the grains between two slides should be 
performed to visualise fungal or bacterial elements 
(Table 1). Specimen should also be cultured 
for fungi and aerobic actinomycetes (Fig. 3). If 
granules are not present, an excisional biopsy for 
culture and histopathology or cytology is essential. 
Histopathology is also important for correlation with 
Fig. 1. Mycetoma of the foot                          
Mycetoma: Microbiological Diagnosis
cultures as the specimens may become contaminated 
with bacteria or fungi from skin or sinus tracts. The 
superficial material from sinus tracts should never be 
sent for culture as it will likely grow mixed flora that 
does not represent the actual cause of infection.
Fig. 2. Discharging grain from a case of mycetoma
Fig. 3. Culture plate and photomicrograph showing Madurella spp.; 
commonest agent of eumycetoma
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Table 1. Common etiologic agents of mycetoma
Etiologic agents Colour of the grains
Eumycetoma species
Madurella mycetomatis Black
Madurella grisea Black
Fusarium spp White
 Acremonium spp White
Actinomycetoma species
 Nocardia brasiliensis White
 Nocardia asteroides White
 Streptomyces somaliensis White
 Actinomadura madurae White
 Actinomadura pelletieri Red
Primary bone tumors are rare with relatively high 
incidence in children and adolescents. They are 
difficult to recognise as malignant by clinicians, 
radiologists, pathologists and leads to major 
diagnostic difficulties.
Table 1 shows 2002 WHO classification of malignant 
bone tumour. Osteosarcoma usually arises in the 
metaphysis of long bones, most commonly around 
the knee. Risk factors for osteosarcoma include 
previous radiation, Paget’s disease of bone and germ 
line abnormalities (Fig. 1). Ewing sarcoma (ES) is 
the second most common bone cancer. About 25 
per cent of the patients have ES of the pelvic bones, 
while 50 per cent have extremity tumours (Fig. 2). 
Chondrosarcoma is most frequently encountered 
in adults arising in the diametaphyseal region of 
long bones. Most of them are low grade (Fig. 3). 
Enchondroma and 
osteochondroma 
can also give rise to 
chondrosarcoma; 
most are solitary 
but can occur as 
multiple lesions. 
Other sarcomas 
like spindle cell 
sarcomas of bone, 
malignant fibrous 
h i s t i o c y t o m a /
f i b r o s a r c o m a , 
lieomyosarcoma, 
undifferentiated 
sarcoma, all 
present with pain 
and fracture.  
Bone Sarcomas: Role of Histopathology in 
Diagnosis 
Dr Fatima A Firdousi
Histopathology
Fig. 1. Conventional osteosarcoma    
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Osteogenic tumours Osteosarcoma,
  Conventional, 
        (chondroblastic, fibroblastic, osteoblastic)
  Telangiectatic,
  Small cell,
  Low-grade central,
  Secondary,
  Parosteal,
  Periosteal,
  High-grade surface
Ewing Sarcoma/ PNET Ewing sarcoma
Cartilage Chondrosarcoma,
  Central, primary and secondary,
  Peripheral,
  Dedifferentiated,
  Mesenchymal,
  Clear cell
Fibrogenic Tumours Fibrosarcoma
Fibrohistiocytic Tumours Malignant fibrous histiocytoma
Haematopoietic Tumours Plasma cell myeloma,
  Malignant lymphoma, NOS
Giant Cell Tumour Malignancy in giant cell tumour
Notochordal Tumour Chordoma
Vascular Tumours Angiosarcoma
Smooth Muscle Tumours Lieomyosarcoma
Lipogenic Tumours Liposarcoma
Miscellaneous Tumours Adamantinoma
Table 1. Classification of bone sarcoma
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The likely diagnosis of a bone tumor is related 
to age. Metastatic neuroblastoma or eosinophilic 
granuloma is seen in children below 5 years while 
primary bone sarcomas are found in children above 
5 years of age. In adult’s greater then 40 years, it is 
usually metastaic or myeloma. 
Radiographs in 2 planes are the first investigation 
to confirm the diagnosis and to localise the 
tumour so that biopsy can be performed. CT 
should be used in a case of diagnostic problem 
or doubt. MRI of the whole bone with adjacent 
joints is the next step for local staging. 
Biopsy should be taken to prevent minimal 
contamination of normal tissue with the 
tumor cells. Samples should be taken for 
microbiological culture and histology. Core 
needle biopsy is preferred and with aid of staging 
studies the primary location of biopsy can be 
chosen. Excision biopsy is contraindicated for 
all cases with a possibility of aggressive and 
benign lesion.
The pathologist should be directly consulted by 
frozen section after taking the biopsy in case more 
material is required. In bone sarcomas, to prevent 
local recurrence biopsy tract should be removed 
with the resection specimen. Biopsy tracts should be 
tattooed by ink.
Material should ideally be transported to the lab within 
half an hour, touch preps can be taken before formalin 
fixation of the biopsy material. All patients should 
have a bone marrow biopsy and aspirate performed 
before starting treatment.
The biopsy request should carry information regarding 
the origin of tumour, preoperative findings and any 
chemotherapy received. Related information should 
also be provided with the biopsy material to the 
laboratory like nature of the bone specimen, segmental 
recession, curettage, needle biopsy, limb amputation 
or any other complex recession.
The bone tumour biopsies are decalcified in 
Histopathology Section at AKUH, The size of the 
tumour measured in 3 dimensions (in mm) with 
histological features and tumour type. Tumour 
necrosis whether less than or more than 90 per cent is 
included. The resection margins whether involved or 
clear by the tumour is also measured in mm. 
Routine H&E staining is performed of the biopsy 
material. In ES special stain like PAS+ and 
immunostain CD99 (MIC 2) is also performed. 
The results of immunohistochemical stains using 
SNOMED or ICD-0 codes are recorded. 
Reference:
Annals of Oncology 21 (Supplement 5):            
v204-v213, 2010
Fig. 3. Chondro sarcoma grade II
Fig. 2. Ewing sarcoma                                 
Fig. 1. B Osteoblastic osteosarcoma
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HLA (Human leukocyte antigen) B-27 is 
class I surface antigen which is encoded by 
genes present on short arm of chromosome 6 
(Fig. 1A). The HLA genes are the human versions 
of MHC genes that are found in most vertebrates. 
The proteins encoded by certain genes are also 
known as antigens, as a result of their historic 
discovery as a factor in organ transplantation. 
The major HLA antigens are essential elements 
for immune function. Different classes have 
different functions. 
The role of HLA B-27 molecules is presentation 
of peptides to T-cells. The immune system uses 
HLAs to distinguish the body its own proteins 
‘self’ from the proteins made by foreign invaders 
such as viruses and bacteria ‘non-self’. HLA B-27 
is strongly associated with the condition ankylosing 
spondylitis, which is named due to the terms 
‘Ankylosing’ or fusing together and ‘spondylitis’ 
or inflammation of bones of spine. This and 
other associated inflammatory diseases are 
collectively referred to as ‘spondyloarthritis’. It is 
uncertain how HLA B-27 causes increase risk of 
ankylosing spondylitis. 
Researchers speculates that HLA B-27 may 
abnormally display to immune system peptides that 
trigger arthritis other researchers suggests that joint 
inflammation characteristic of this disorder may 
result from improper folding of HLA B-27 protein 
or the presence of abnormal forms of the protein on 
the cell surface.
Ankylosing spondylitis is two to three times more 
common in males than in females, and it affects all 
age groups including children. The most common 
age of onset of symptoms is the second and third 
decade of life. The effect of the disease is depicted 
in Fig. 1B Symptoms of ankylosing spondylitis 
include back pain and stiffness (worst at night and 
in morning), weight loss, feeling unwell, tiredness, 
pain and swelling of hips, knee or joints, plantar 
fasciitis (pain under heel of foot), aching in chest, 
around ribs. It may be associated with psoriatic, 
colitic and reactive arthiritis. The complications of 
the disease are uveitis (inflammation of eye) and 
issues related to heart and lungs.
HLA B-27 at a Glance
Sheeba Parveen 
Molecular Pathology
Fig.1.B. Diagrammatic representation of the effect of ankylosing spon-
dylitis on the spine.
Fig.1.A. The organization of HLA genes on chromosome 6
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Meeting Reports
Multiple CME seminars were held at different cities in 
Pakistan as a part of continuing educational activities 
of the Department of Pathology  and Microbiology, 
where faculty presented the latest advancements 
and updates in medical and laboratory sciences.
CME Seminar held at Hotel City Centre Baldia 
Complex, Mirpurkhas on February 09, 2011, 
covered broad range of topics on chronic hepatitis 
B and hepatitis C interpretation, diagnosis and 
management, vitamin D deficiency and  approach 
to diagnosis of anaemia. It was well attended by 
general practitioners, physicians, surgeons, 
of District Civil Hospital, Muhammad 
Medical college Hospital Mirpurkhas and 
nearby periphery towns i.e. Digri, Umer Kot, and 
Tando Allahyar. 
Dr Yasmeen Khoonharo, Assistant Professor 
and Consultant Gynaecologist and Obstetrician, 
Muhammad Medical College Mirpurkhas 
appreciated role of AKUH pathologists in educating 
as well as providing high quality diagnostic 
services for physicians and hospitals nationwide.
Dr Mahadev Harani referred to data obtained by 
the AKUH Clinical Laboratories for differential 
diagnosis of anaemia with histogram. He 
emphasised diagnosis and management of anaemia 
by detail history and laboratory investigations.
Dr  Aysha Habib Khan Consultant Chemical 
pathologist, highlighted the wide spread 
prevalence of vitamin D deficiency in Pakistan, 
She presented data from healthy volunteers and 
Fig. 2. Detection of the HLA B-27 all  ele. The picture depicts the pres-
ence of DNA on an agarose gel stained with ethi dium bromide. Fluores-
cent bands indicate the presence of DNA in each lane
For molecular diagnosis of ankylosing spondylitis 
a venous blood sample is required for the test. 
DNA is extracted from blood using the sodium 
dodecyl sulphate (SDS)-proteinase K lyses method 
and then amplified by conventional polymerase 
chain reaction (PCR). Using Sequence specific 
primer (HLA-A and HLA–B) primers. In addition, 
PCR for the growth hormones (GH 1 and GH 2) genes 
is used as an internal control. Amplified product is 
than analysed by agarose gel electrophoresis (Fig. 
2).
A positive band of 144 kb obtained in the PCR 
reaction indicates the presence of the HLA-B27 
allele, and based on this the result of the test is 
reported as a ‘presence’ or an ‘absence’ of the 
HLA B27 allele. An internal control is included in 
each PCR reaction to monitor the presence of PCR 
inhibitors in the specimen.
Presenters and organisers of the CME at Mirpur Khas
Seema Vaqar
Clinical Labortory
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ambulatory care patients highlighting the need 
to diagnose and treat these case at an early stage. 
She shared that testing in form of bone health 
profile is available at AKUH Clinical Lab; the 
profile is developed to answer the potential 
clinical questions that a physician has, if a patient 
is suspected of having a metabolic bone diseases. 
Dr Syed Zafar Abbas Consultant Physician and 
Gastroenterologist, Medical Superintendent 
Muhammad Medical Hospital Mirpurkhas and 
Dr Romena Qazi Assistant Professor and 
Section head Molecular Pathology AKU both 
address the chronic issue of hepatitis B and C 
prevalence and management of the infection, 
diagnosis of Hepatitis C by PCR was emphasised 
and stressed by the speakers as an important step in 
management.
CME held on February, 9 2011 at Fatima Memorial 
Hospital College of Medicine and Dentistry Lahore, 
was well attended by health care professionals
and consultants from all disciplines of Hospital. 
Dr Farooq Ghani, Associate Professor and Director 
out reach laboratory services addressed about 
‘Diagnostic Approach to Genetic Disorders’ and 
Triple Marker Screening test.  He introduced 
advancement in technology and importance of 
maternal blood screening test for Down’s syndrome 
and neural tube defects in his presentation. Dr 
Sara Malik explained about ‘Serum Markers in 
Prenatal Diagnosis’, where the fetus is treated as 
patient. She shared that approximately three per 
cent of all pregnancies have a genetic disorder or 
birth defect. Dr Ayesha Ehsan in her presentation 
explained about maternal blood sampling 
for testing for fetal DNA in maternal blood.
CME seminar was held at Thalassaemia Care 
Center, Badin with on 22nd February 2011. 
Dr Muhammad Haroon, Pathologist at Civil 
hospital and In-charge Thalassaemia Care Center
at Badin presided over the session.
Dr Bushra Moiz, Associate Professor and Consultant 
Haematologist, AKUH delivered an interactive 
talk on ‘How to investigate a bleeding patient?’ 
She emphasised on taking a detailed history of a 
bleeding patient along with physical examination 
and recommended complete blood count with 
peripheral film review for correct platelet estimation, 
bleeding time (BT), prothrombin time (PT), 
activated partial thromboplastin time (APTT) and 
urea-clot lysis test as first line tests. The 
last is required to detect factor XIII deficiency 
Speakers at CME Seminar on Recent Advances in Pediatrics Pathology
Dr Farooq Ghani addressing the audience at CME
Dr Sara Malik receiving her shield from Prof. Sabiha Riyaz
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Answer to LABRAD Quiz
which cannot be tested by PT and APTT alone. She 
emphasised the review of platelet film in case of low 
platelets as spurious results are sometimes generated 
by analysers in the presence of platelet clumps and 
large or giant platelets. The screening tests assist in 
making a presumptive diagnosis in conjunction with 
clinical details. Based on these tests, the doctor 
should order more specific tests e.g if von Willebrand 
disease is suspected than vWAg, RiCof and factor 
VIII assay are required for proper evaluation. She 
also stressed that all such patients should be referred 
to haematologists for proper assessment. Ordering 
of all tests is neither required nor financially viable 
hence an appropriate understanding of underlying 
pathology is utmost essential for correct diagnosis 
and management of the bleeding disorder. AKUH 
laboratory offers all routine and specialized 
tests required for diagnosis of various 
bleeding disorders.
The talk was followed by a question-and-answer 
session where doctors showed their keen interest in 
management of bleeding disorders.
CME Seminar on ‘Recent Advances in 
Pediatrics Pathology’ was held at auditorium 
of King Edward Medical University/
Mayo Hospital Lahore on March 8th 2011 
Professor Mahmood Shaoukat shared his vision 
about the ‘Use of Stem Cells in Trauma and Burn 
Management. Prof Farah Asghar explained about 
‘Fetal anomalies screening’. She stated that 
congenital abnormalities account for 20-25 per 
cent of prenatal deaths. Dr Farooq Ghani spoke 
about the ‘Prenatal Diagnosis of Birth Defects’ 
and explained the techniques and methods 
of prenatal testing. He talked about common 
chromosomal and genetic disorders seen in our 
population and shared his experience of prenatal 
testing at AKU. 
Dr Shahid Pervaiz, Professor Department of 
Pathology and Microbiology  presented about the 
common childhood leukemias and lymphomas seen 
in our population and how the accurate diagnosis 
can impact patient management. 
1.1: Hypoparathyroidism is the most common 
 cause of hypocalcemia, which is causing 
 symptoms in this patient. Her presentation 
 soon after birth suggests presence of 
 congenital hypoparathyroidism.
1.2: Serum magnesium levels: Magnesium is 
 required for optimal activity of parathyroid 
 gland. Levels are usually low in 
 hypoparathyroidism.
1.3: The goal of treatment is to normalise the 
 levels of calcium, magnesium and 
 phosphorus. A treatment regimen typically
 includes replacing calcium by giving 
 oral calcium carbonate or gluconate along 
 with 1 alpha vitamin D.
2.1: Symptoms of bone pain and weakness 
 can mean that patient have a coexistent 
 vitamin D deficiency along with senile 
 osteoporosis. For many people, the symptoms 
 are subtle. Yet even without bone symptoms,
 inadequate vitamin D levels can pose other
 health risks
2.2: Biochemical tests to measure calcium, 
 phosphorus, magnesium, vitamin D and 
 parathyroid hormone and bone turnover 
 markers can be performed. Depending 
 upon the symptomatology, tests to screen for 
 secondary osteoporosis can also be considered.
2.3: Bone tumor markers (BTM) are helpful 
 in monitoring bisphosphonate therapy. 
 Early changes in BTM measure the clinical
 efficacy of an anti-resorptive treatment 
 and to reinforce patient compliance. At
 AKUH Clinical Laboratory, N-telopeptide of 
 Type I collagen is performed.
www.aku.edu/akuh/hs/cs/pathology.shtml
